- Open Access
Effect of norepinephrine dosage on mortality in patients with septic shock
Journal of Intensive Carevolume 6, Article number: 12 (2018)
Use of high-dose norepinephrine is thought to have an immunosuppressive action that increases mortality. This study aimed to evaluate the correlation between norepinephrine dosage and prognosis of patients with septic shock.
This study was a nested cohort of the DExmedetomidine for Sepsis in Intensive Care Unit Randomized Evaluation (DESIRE) trial. We evaluated 112 patients with septic shock and an initial Sequential Organ Failure Assessment Cardiovascular (SOFA-C) category score > 2 and initial lactate level > 2 mmol/L. We divided the patients into two groups according to the norepinephrine dosage administered over the initial 7 days: high dose (≥ 416 μg/kg/week) (H group, n = 56) and low dose (< 416 μg/kg/week) (L group, n = 56). The primary outcome of interest was 28-day mortality. Secondary outcomes were ventilator-free days, initial 24-h infusion volume, initial 24- to 48-h infusion volume, and the need for renal replacement therapy. For comparisons between the H group and L group, we used the chi-square test or Fisher’s exact test for categorical variables and the t test or Wilcoxon rank sum test for continuous variables. For time-to-event outcomes, Cox proportional hazards models were used. Kaplan-Meier survival curves were created for graphical representation.
Patient characteristics appeared to be similar between the two groups except for the SOFA-C score and fibrinogen degradation product level. The cumulative incidence of death at 28 days was 29.9% (16 patients) in the L group and 29.7% (15 patients) in the H group (p = 0.99). The median number of 28-day ventilator-free days was 20 (0, 25) in the L group and 16 (0, 22) in the H group (p < 0.05). Initial infusion volume at 0–24 h in the H group was significantly higher than that in the L group (p = 0.004). Infusion volume at 24–48 h in the H group was also significantly higher than that in the L group (p = 0.03).
No statistically significant difference was observed in 28-day mortality between patients with septic shock treated with high-dose norepinephrine compared with those treated with low-dose norepinephrine. However, the number of ventilator-free days in the L group was higher than that in the H group.
clinicaltrials.gov Identifier: NCT01760967 Date of trial registration: January 4, 2013.
Norepinephrine is the vasopressor of first choice for patients with septic shock . Norepinephrine recruits unstressed volume through alpha adrenergic effects on venous and arterial vessels and might recruit volume to the macrovasculature. However, norepinephrine is also thought to have an immunosuppressive action that causes a poor prognosis [2, 3]. Previous reports showed that norepinephrine dosage was associated with intensive care unit (ICU) mortality, with an especially high mortality rate at doses above 1 μg/kg per min . From this previous study, the high-dose usage of norepinephrine was thought to cause high mortality in patients with sepsis. As another problem, in the treatment strategy of septic shock, it is important to include early recognition, fluid resuscitation, and maintenance of the blood pressure. However, if massive fluid resuscitation is required, this can cause pulmonary edema and prolonged the number of ventilator days. In this study, we aimed to evaluate the correlation between norepinephrine dosage and prognosis and the number of ventilator-free days (VFD) of patients with septic shock.
The DExmedetomidine for Sepsis in Intensive Care Unit Randomized Evaluation (DESIRE) trial was conducted from February 2013 to January 2016 . This trial was a multicenter, randomized, controlled trial that enrolled 201 adult patients with sepsis undergoing ventilation. It was designed to assess the effects of a sedation strategy with dexmedetomidine compared with that without dexmedetomidine. The results of this trial in the 201 patients showed that treatment with dexmedetomidine vs that without dexmedetomidine did not significantly reduce the number of VFD (20 vs 18 days) or 28-day mortality (23 vs 31%, hazard ratio 0.69). This sub-analysis of the 201 randomized patients included those with septic shock. Septic shock was defined as a Sequential Organ Failure Assessment (SOFA) score > 2 for the cardiovascular category and a lactate level > 2 mmol/L at randomization. We enrolled 112 patients and divided the patients into two groups according to the total dosage of norepinephrine administered over the initial 7 days: low dose (< 416 μg/kg/week) (L group, n = 56) and high dose (≥ 416 μg/kg/week) (H group, n = 56) (Fig. 1).
The treatment protocol for sepsis was based on the Guidelines for the Management of Sepsis . In the resuscitation from septic shock-induced hypoperfusion, we initially administered an adequate amount of crystalloid on admission to maintain a mean arterial pressure of 65 mmHg, central venous pressure of 8–12 mmHg, and urinary output of > 0.5 mL/kg/h. Following fluid resuscitation, if the blood pressure could not be maintained, we used norepinephrine or vasopressin as the vasopressor.
We collected data on the initial serum lactate level, SOFA score, and Acute Physiology and Chronic Health Evaluation II (APACHE II) score at randomization. White blood cell (WBC) count, levels of fibrinogen, D-dimer, fibrinogen degradation products (FDP), C-reactive protein (CRP), and procalcitonin (PCT) and norepinephrine dosage were assessed. Infusion volume was assessed on the first and second days, and the dosages of other vasopressors were assessed on the first 7 days after randomization.
The primary outcome of interest was 28-day mortality. For other outcomes, patients were followed in the hospital from enrollment for 28 days or until discharge or death if earlier. Secondary outcomes included the number of VFD, defined as the number of days without use of a ventilator during the 28-day study period, initial 24-h infusion volume, initial 24- to 48-h infusion volume, and the need for renal replacement therapy including continuous renal replacement therapy and hemodialysis.
Continuous variables are presented as the mean ± standard deviation (SD) or the median and interquartile range (IQR). Categorical variables are presented as numbers and percentages (%). For comparisons between the H group and L group, we used the chi-square test or Fisher’s exact test for categorical variables and the t test or Wilcoxon rank sum test for continuous variables.
For time-to-event outcomes (time to ICU discharged death), Cox proportional hazards models were used. Kaplan-Meier survival curves were created for graphical representation of these time-to-event outcomes. When examining 28-day mortality, patients were censored at the time of last contact while alive or at 28 days from enrollment, whichever came first. Censoring for hospital discharge analyses occurred at the time of death or, rarely, at study withdrawal. To account for any effect of site and for baseline imbalances, a Cox proportional hazards regression model was used with patients nested within site, and site treated as a random effect with the following covariates included in the model: APACHE II score > 23, age > 65, emergency operation, infection site is lung, and treated with dexmedetomidine. A two-sided p value of < 0.05 was considered statistically significant, and all analyses were performed using JMP Pro software (version 12.2; SAS Institute Inc., Cary, NC, USA).
Patient characteristics appeared to be similar between the two groups except for the Sequential Organ Failure Assessment Cardiovascular (SOFA-C) score and FDP level (Table 1). In the H group, use of another vasopressor, such as dobutamine, and total vasopressin dosage within 7 days were significantly higher than those in the L group. Causes of sepsis were lung (n = 29), abdomen (n = 52), and others (n = 31).
As the primary outcome, the cumulative incidence of death at 28 days was not significantly different between the two groups: 29.9% (16 patients) in the L group and 29.7% (15 patients) in the H group (p = 0.99) (Fig. 2). The analysis adjusted for infusion volume over the first 24 h also did not show a significant difference (p = 0.38). The median 28-day VFD in the L group was significantly higher than that in the H group (20 [0, 25] vs 16 [0, 20] days: p < 0.05) (Fig. 3). Using the Cox proportional hazards model to adjust for all five of the covariates, VFD was incorporated into the model, with similar results compared with the primary analysis. The dose of norepinephrine used was significantly different between the two groups on each of the first 7 days. Especially, the highest dose of norepinephrine administered was in the H group on day 2 at 345.1 (170.9) μg/kg (Fig. 4).
Initial infusion volume at 0–24 h in the H group was significantly higher than that in the L group (7829 [5689, 10,676] vs 5544 [3985, 8000] mL, p = 0.004). Infusion volume at 24–48 h in the H group was also significantly higher than that in the L group (3530 [2382, 4612] vs 2689 [1962, 3916] mL, p = 0.03). Within the first 3 days after admission, 7 patients died in the H group and 9 patients died in the L group. The cumulative incidences of death at 28 days except for the patients with death within 3 days were not significantly different between the two groups: 32.8% in the L group and 28.4% in the H group (p = 0.39). Renal replacement therapy was performed in 32 patients in the H group and in 18 patients in the L group.
Septic shock is defined as a subset of sepsis in which underlying abnormalities of circulatory and cellular metabolism are profound enough to substantially increase mortality . Norepinephrine is the vasoactive agent of first choice for patients with septic shock after adequate volume resuscitation . Our results showed that the dosage of norepinephrine did not affect the mortality of patients with septic shock, but the number of VFD was lower in the H group. The reason for the difference in the number of VFD between the two groups was that the infusion volume in the H group was significantly higher than that in the L group. Massive infusion volumes can bring about pulmonary dysfunction and cardiovascular failure. Generally, such conditions require ventilator support. Thus, we thought that the factors contributing to the lower number of VFD in the H group were the unstable circulatory status and massive infusion volume administered. A previous report showed that a norepinephrine dosage of 1 μg/kg per minute was associated with an ICU death rate of 90% and suggested that a dosage of norepinephrine greater than 1 μg/kg per minute is an independent factor associated with mortality in patients with septic shock . However, the study by Martin and colleagues had a few problems related to fluid treatment for septic shock. The non-survivors group did not receive the same resuscitation infusion volume as the survivors group. Crystalloid was 1.0 L (0.0–2.5) in the 168 survivors vs 1.0 L (0.0–2.0) in the 156 non-survivors, and cumulative fluid administration was 1.5 L (0.9–3.0) in the 168 survivors vs 1.0 L (0.5–2.0) in the 156 non-survivors . These results indicate that the non-survivors were not infused with an adequate amount of resuscitation volume in the initial period.
In our study, the H group received an adequate amount of resuscitation fluid compared with the L group over the initial 24 h and at 48 h. The most important treatment strategy for patients with septic shock is initial fluid resuscitation and maintenance of the blood pressure. If patients with septic shock receive adequate infusion of fluid volume, the dose of norepinephrine may not be related to patient prognosis.
In previous in vitro and animal studies, norepinephrine was shown to exert multiple anti-inflammatory actions [6, 7]. Exogenous norepinephrine infused into the portal vein of rats resulted in elevation of serum levels of IL-10 and IL-1 beta [8, 9]. Another study showed neutrophils incubated with norepinephrine displayed an immunosuppressive phenotype [10,11,12]. These studies indicate that epinephrine may have anti-inflammatory effects. In contrast, clinical studies have not investigated norepinephrine in relation to immunosuppressive reactions. Some studies investigating the correlation of the dosage of norepinephrine with mortality indicated that a high norepinephrine level is associated with high mortality in patients with septic shock . However, no study found any correlation between the dosage of norepinephrine and immunological parameters. The blocking action of endogenous catecholamine with β-blockers has improved the prognosis in patients with sepsis [14, 15] and reduced secondary infection in pediatric burn patients . These clinical studies suggested that a high catecholamine level may have led to immunoparalysis [17, 18].
In our study, some alternative vasopressors were also used to treat the patients with septic shock. More dobutamine, vasopressin, and renal replacement therapy were used in the H group than in the L group. However, mortality was not significantly different between the two groups. Our results indicated that renal replacement therapy and total dobutamine dosage also did not affect mortality. We surmise that because of the greater inflammatory action in the H group, the patients did not respond to the epinephrine effect and required the use of vasopressin and another vasopressor to maintain their blood pressure. The patients in a severe condition died earlier, and as a result, the doses of norepinephrine or another vasopressor in these patients might be smaller. We also assessed the incidence of death at 28 days after excluding the patients who died within 3 days. However, there was no significant difference between the two groups, and thus we thought that the early death of some patients had no influence on mortality.
Several adverse effects of catecholamines were reported previously, such as pulmonary edema, bowel ischemia, immunomodulation, increase cellular energy expenditure, and hyperglycemia [19,20,21]. Generally, we believed that a high concentration of catecholamine would increase mortality and worsen patient prognosis. However, our results were contrary to those of previous reports and did not indicate that high norepinephrine usage worsened mortality or caused organ dysfunction such as bowel ischemia and pulmonary edema although we did not measure the actual catecholamine concentration in serum. We think that high-dose norepinephrine may be used safely with no associated complications.
This study has several limitations. First, it was a nested cohort of a randomized control study, and use of a vasopressor other than norepinephrine was not allowed by the treatment protocol. Our study concentrated on the use of noradrenaline as the initial vasopressor, and use of another vasopressor was uneven. Second, use of an alternate vasopressor other than norepinephrine was left to each physician’s judgment. Third, we cannot determine to what extent the mechanism of norepinephrine contributed to the change in mortality. Also, the duration of shock was similar because there was no significant difference in initial lactate levels and APACHE II scores between the two groups. However, the initial SOFA-C score was different. We attribute this difference in SOFA-C score to the catecholamine dosage in the two groups because the initial blood pressure was not different between the groups. The early recognition and treatment of septic shock in our patients may be one factor influencing our results. However, the greater inflammatory action occurring in the H group required a high-dose vasopressor.
There was no statistically significant difference in 28-day mortality between the patients with septic shock treated with high-dose norepinephrine vs those treated with low-dose norepinephrine. However, the number of VFD was significantly higher in the group treated with low-dose norepinephrine than in the group treated with high-dose norepinephrine.
- APACHE II:
Acute Physiology and Chronic Health Evaluation II
Fibrinogen degradation products
Intensive care unit
Sequential Organ Failure Assessment
Sequential Organ Failure Assessment Cardiovascular
White blood cell
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–77.
Martin C, Medam S, Antonini F, Alingrin J, Haddam M, Hammad E, et al. Norepinephrine: not too much, too long. Shock. 2015;44:305–9.
Stolk RF, van der Poll T, Angus DC, van der Hoeven JG, Pickkers P, Kox M. Potentially inadvertent immunomodulation: norepinephrine use in sepsis. Am J Respir Crit Care Med. 2016;194:550–8.
Kawazoe Y, Miyamoto K, Morimoto T, Yamamoto T, Fuke A, Hashimoto A, et al. Effect of dexmedetomidine on mortality and ventilator-free days in patients requiring mechanical ventilation with sepsis: a randomized clinical trial. JAMA. 2017;317:1321–8.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801–10.
Lyte M, Freestone PP, Neal CP, Olson BA, Haigh RD, Bayston R, et al. Stimulation of Staphylococcus epidermidis growth and biofilm formation by catecholamine inotropes. Lancet. 2003;361:130–5.
Lyte M, Bailey MT. Neuroendocrine-bacterial interactions in a neurotoxin-induced model of trauma. J Surg Res. 1997;70:195–201.
Zhou M, Das P, Simms HH, Wang P. Gut-derived norepinephrine plays an important role in up-regulating IL-1beta and IL-10. Biochim Biophys Acta. 2005;1740:446–52.
Woiciechowsky C, Asadullah K, Nestler D, Eberhardt B, Platzer C, Schoning B, et al. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med. 1998;4:808–13.
Tsuda Y, Kobayashi M, Herndon DN, Suzuki F. Impairment of the host’s antibacterial resistance by norepinephrine activated neutrophils. Burns. 2008;34:460–6.
Dunser MW, Ruokonen E, Pettila V, Ulmer H, Torgersen C, Schmittinger CA, et al. Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care. 2009;13:R181.
Povoa PR, Carneiro AH, Ribeiro OS, Pereira AC. Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study). Crit Care Med. 2009;37:410–6.
Yoshigi M, Hu N, Keller BB. Dorsal aortic impedance in stage 24 chick embryo following acute changes in circulating blood volume. Am J Phys. 1996;270(5 Pt 2):H1597–606.
Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310:1683–91.
Macchia A, Romero M, Comignani PD, Mariani J, D'Ettorre A, Prini N, et al. Previous prescription of beta-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis. Crit Care Med. 2012;40:2768–72.
Jeschke MG, Norbury WB, Finnerty CC, Branski LK, Herndon DN. Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children. J Trauma. 2007;62:676–81.
Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306:2594–605.
Leentjens J, Kox M, van der Hoeven JG, Netea MG, Pickkers P. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med. 2013;187:1287–93.
Dunser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med. 2009;24:293–316.
Schmittinger CA, Torgersen C, Luckner G, Schroder DC, Lorenz I, Dunser MW. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med. 2012;38:950–8.
de Montmollin E, Aboab J, Mansart A, Annane D. Bench-to-bedside review: beta-adrenergic modulation in sepsis. Crit Care. 2009;13:230.
We would like to thank the DESIRE Trial Investigators: Akihiro Fuke, MD (Osaka City General Hospital, Osaka, Japan); Atsunori Hashimoto, MD (Hyogo College of Medicine, Nishinomiya, Japan); Hiroyuki Koami, MD (Saga University Hospital, Saga, Japan); Satoru Beppu, MD (National Hospital Organization Kyoto Medical Center, Kyoto, Japan); Yoichi Katayama, MD (Sapporo Medical University, Sapporo, Japan); and Makoto Itoh, MD (Yamaguchi Grand Medical Center, Yamaguchi, Japan).
The original study was supported in part by a noncontractual research grant to Wakayama Medical University provided by Hospira Japan.
Availability of data and materials
The datasets generated during and/or analyzed during the present study are not publicly available owing to currently ongoing research studies, but the data are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
This study was approved by the institutional review boards of Wakayama Medical University and each participating institution. All patients provided necessary consent to participate in this study.
Consent for publication
No individual personal data are included in the study. All patients provided necessary consent to participate in this study.
Dr. Yamamura reports receipt of lecture fees from Hospira Japan, Nipro, and Asahi Kasei and educational consulting fees from Toray Industries, CSL Behring, Teijin Pharma, and Nihon Pharmaceutical. Dr. Kawazoe reports receipt of lecture fees from Hospira Japan and Pfizer Japan and a scholarship from Hospira Japan. Dr. Miyamoto reports receipt of lecture fees from Becton Dickinson and Pfizer Japan. Dr. Morimoto reports receipt of lecture fees from AbbVie, AstraZeneca, Daiichi-Sankyo, Kowa, Kyorin, Mitsubishi-Tanabe, and Pfizer Japan and consulting fees from Asahi Kasei and Boston Scientific. Dr. Tomonori Yamamoto and Dr.Yoshinori Ohta, have no competing interests. The other authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.